您的瀏覽器不支援JavaScript功能,若網頁功能無法正常使用時,請開啟瀏覽器JavaScript狀態
:::
  
Professor Thierry Burnouf, Vice-Dean of CBME, Director of IPPME/GIBMTE, was invited as key note speaker at the Regional Asia-Pacific Congress of the International Society of Blood Transfusion (ISBT) in Guanzhou , China (Nov. 26-28, 2017) to talk about the “use of outdated human platelet concentrates in cell therapy and regenerative medicine”. He was also the chairman of a session on novel blood products. The congress was attended by over 2000 participants from numerous countries in Asia-Pacific and around the world. This illustrates that CBME of TMU is among the leading group in the world in these novel developments of platelet concentrates.  
 

  
Professor Thierry Burnouf, Vice-Dean of CBME, Director of IPPME/GIBMTE, was invited as a speaker at the Congress of the German Society of Blood Transfusion and Hematology (DGTI) in Cologne, Germany (Oct. 25-27, 2017). He addressed the topic of “Commercial production and new developments in platelet lysates including pathogen inactivation and prion removal.” Virus and prion safety of human platelet lysates is a major research and development focus of bio-engineered platelet lysates for cell therapy, regenerative medicine, and tissue engineering.
 

  
Professor Thierry Burnouf, Vice-Dean of CBME, Director of IPPME/GIBMTE, was invited as the special honorary guest of the Asahi Kasei Medical Planova workshop in Prague, Czech Republic (Nov 8-10, 2017). Prof Burnouf was a pioneer in the 1990’s in the industrial implementation of nanofiltration, using dedicated hollow fiber membranes, for virus removal from therapeutic human plasma-derived products (coagulation factors, immunoglobulins, protease inhibitors, etc.). His work contributed to ensuring optimal virus safety of industrial therapeutic plasma products used to treat patients suffering from bleeding and immunological disorders. His talk in Prague described his over than 25 years dedicated work to ensuring the safety of therapeutic plasma products. Prof Burnouf’s laboratory continues further development in virus safety of blood-derived products through Academy-Industry cooperation between TMU and Asahi Kasei Medical, Japan.


     
Professor Thierry Burnouf, Vice-Dean of CBME, Director of IPPME/GIBMTE, was invited as a speaker at the Merck Plasma China Seminar “advancing together in plasma processing and technologies” in Shanghai, China (Nov 13-14, 2017). Prof Burnouf’s talk was presenting “Studies to optimize the applications of Merck Fractogel anion-exchange chromatography resin for one-step purification of  caprylic acid-treated IVIG streams ». These studies intend to develop procedures for optimal quality and safety of therapeutic plasma-derived immunoglobulins G used to treat patients suffering from immunodeficiency or other immunological disorders. Immunoglobulins are on the WHO Model List of Essential Medicine. Prof Burnouf’s laboratory at CBME has several Academy-Industry cooperation contracts between TMU and Merck-Millipore, USA.